spacer
home > white papers > Personalised Medicine - Pharma and Dx Firms Share Wider Horizons - DiagnostikNet-BB
WHITE PAPERS
logo_Diagnostiki.jpg

DiagnostikNet-BB

phone +49 (0) 3302 55 199-14
email f.adams@diagnostiknet-bb.de
web http://www.diagnostiknet-bb.de
email Neuendorfstraße 17/ 16761 Hennigsdorf

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
Personalised Medicine - Pharma and Dx Firms Share Wider Horizons
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Wire it with pride with Teknomeks latest modular storage options

Teknomek has extended its modular shelving range to offer customers more options to make optimal use of the storage space available to them. The hygienic units are built from 304 grade stainless steel and feature wire shelving, which does not interrupt air circulation and prevents from dust settling.
More info >>


White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>


Industry Events

Partnerships in Clinical Trials Europe 2018

27-29 November 2018, CCIB, Barcelona

Partnerships in Clinical Trials Europe is back – and bigger than ever. Europe’s most complete clinical meeting is bringing together 1000+ of the industry’s leading experts this November for it’s 17th annual gathering, and you’re invited!
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement